Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

78 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression.
Keiser PB, Biggs-Cicatelli S, Moran EE, Schmiel DH, Pinto VB, Burden RE, Miller LB, Moon JE, Bowden RA, Cummings JF, Zollinger WD. Keiser PB, et al. Among authors: Zollinger WD. Vaccine. 2011 Feb 4;29(7):1413-20. doi: 10.1016/j.vaccine.2010.12.039. Epub 2011 Jan 1. Vaccine. 2011. PMID: 21199704 Clinical Trial.
Evaluation of a whole-blood cytokine release assay for use in measuring endotoxin activity of group B Neisseria meningitidis vaccines made from lipid A acylation mutants.
Stoddard MB, Pinto V, Keiser PB, Zollinger W. Stoddard MB, et al. Among authors: Zollinger W. Clin Vaccine Immunol. 2010 Jan;17(1):98-107. doi: 10.1128/CVI.00342-09. Epub 2009 Nov 18. Clin Vaccine Immunol. 2010. PMID: 19923573 Free PMC article.
Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease.
Boslego J, Garcia J, Cruz C, Zollinger W, Brandt B, Ruiz S, Martinez M, Arthur J, Underwood P, Silva W, et al. Boslego J, et al. Among authors: Zollinger W. Vaccine. 1995 Jun;13(9):821-9. doi: 10.1016/0264-410x(94)00037-n. Vaccine. 1995. PMID: 7483804 Clinical Trial.
Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005.
Borrow R, Carlone GM, Rosenstein N, Blake M, Feavers I, Martin D, Zollinger W, Robbins J, Aaberge I, Granoff DM, Miller E, Plikaytis B, van Alphen L, Poolman J, Rappuoli R, Danzig L, Hackell J, Danve B, Caulfield M, Lambert S, Stephens D. Borrow R, et al. Among authors: Zollinger W. Vaccine. 2006 Jun 12;24(24):5093-107. doi: 10.1016/j.vaccine.2006.03.091. Vaccine. 2006. PMID: 16838413 No abstract available.
An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups.
Pinto VB, Moran EE, Cruz F, Wang XM, Fridman A, Zollinger WD, Przysiecki CT, Burden R. Pinto VB, et al. Among authors: Zollinger WD. Vaccine. 2011 Oct 13;29(44):7752-8. doi: 10.1016/j.vaccine.2011.07.124. Epub 2011 Aug 7. Vaccine. 2011. PMID: 21827811
Importance of antibodies to lipopolysaccharide in natural and vaccine-induced serum bactericidal activity against Neisseria meningitidis group B.
Schmiel DH, Moran EE, Keiser PB, Brandt BL, Zollinger WD. Schmiel DH, et al. Among authors: Zollinger WD. Infect Immun. 2011 Oct;79(10):4146-56. doi: 10.1128/IAI.05125-11. Epub 2011 Jul 18. Infect Immun. 2011. PMID: 21768280 Free PMC article. Clinical Trial.
A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA.
Keiser PB, Gibbs BT, Coster TS, Moran EE, Stoddard MB, Labrie JE 3rd, Schmiel DH, Pinto V, Chen P, Zollinger WD. Keiser PB, et al. Among authors: Zollinger WD. Vaccine. 2010 Oct 8;28(43):6970-6. doi: 10.1016/j.vaccine.2010.08.048. Epub 2010 Aug 21. Vaccine. 2010. PMID: 20732470 Clinical Trial.
78 results
Jump to page
Feedback